The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Please consult the full Prescribing Information for additional ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q4 Results for ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK’s share price has fallen a long way on ... nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk.

GSK has teamed up with the University ... changes in cells in precancerous stages that could form the basis of vaccines to prevent full-blown cancer from developing. The pharma group has pledged ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare ... has moved to take full control of the CAR-T ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

The E.W. Scripps Company has entered into a transaction support agreement (TSA) with lenders representing more than 70% of the aggregate principal amount of Scripps' outstanding tranche B-2 term loans ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously tr ...